Abstract. A syndrome of periodic catecholamine and prostaglandin E2 discharge is described in 2 patients aged 17 and 3 years. They had recurrent attacks of vomiting, hypertension and psychotic depression for several years with a fixed periodicity. At 
staglandin E2 were markedly elevated, whereas dopamine was undetectable. This resulted in hypercortisolemia, hyponatremia and oliguria, which were completely normalized when the attack subsided. Dopaminergic inhibition by metoclopramide injection induced a sustained rise in plasma bicyclo-prostaglandin E2 in the patients, a transient rise in 4 controls, and no response in 8 control children. The 4 control responders had significantly higher plasma norepinephrine levels and aldosterone responses than the non-responders (P < 0.001). There was a linear correlation between peak values of bicyclo-prostaglandin E2 and basal norepinephrine levels (r = 0.990, P < 0.001). The patients released bicyclo-prostaglandin E2 and aldosterone more easily than the control responders in terms of plasma norepinephrine and dopamine levels. Treatment of the patient with clonidine was partially effective, whereas administration of indomethacin completely suppressed recurrence of the attacks for 1 year. These results suggest the etiologic possibility that the patients have a decreased dopaminergic inhibition of prostaglandin E2-mediated norepinephrine secretion, which causes periodic discharge of norepinephrine and concomitant release of ACTH and AVP.
Recurrent abdominal pain and vomiting are com¬ mon symptoms associated wtih a variety of dis¬ orders in childhood. Now the diagnosis of 'cyclic vomiting' has been eliminated from the standard textbook of pediatrics because it is regarded as a symptom of various underlying diseases rather than a clinical entity. However, we descried previ¬ ously a syndrome of severe vomitings, hyperten¬ sion and psychotic depression without any defi¬ nite lesion, which recurred periodically for several years (Sato et al. 1980 (Sato et al. , 1982 . On the initiation of the attack, plasma ACTH and AVP were marked¬ ly elevated, resulting in hypercortisolemia, hypo¬ natremia and hypo-osmolality in plasma. Urinary flow was diminished and oligura was followed by polyuria at the end of the attack. Plasma norepi¬ nephrine (NE) was increased, which appeared to be the cause of hypertension. All these signs and laboratory abnormalities were completely absent during periods of remission. Since there had been no description of a similar disorder in the litera¬ ture, we reported the patient as a syndrome of periodic ACTH and AVP discharge (Sato et al. 1982 (Hedqvist 1977) and PGEmediated feedback control of CA secretion has been postulated (Samuelson & Wennmalm 1971; Jungstad & Wennmalm 1973) . It is difficult, how¬ ever, to study the control mechanism in clinical materials because of the rapid degradation of PGE in the circulation (Granström et al. 1982 ).
Recent technical advances have made it possible to measure the plasma concentration of PGE2 after converting it to a stable metabolite, bicyclo-PGE2 (cPGE2) (Bothwell et al. 1982; Demers et al. 1983 ).
This prompted us to examine the interrelation between PGE2 and CA release in patients with this syndrome using a DA antagonist, metoclopramide (Plouin et al. 1976; Agabiti-Rosei et al. 1977) . Another patient recently diagnosed was also in¬ cluded in the study.
Subjects and Methods
Two girls aged 17 and 3 years with this syndrome were examined. Clinical data of the older patient (No. 1) were previously reported in detail (Sato et al. 1980 Fig. 1 .
at the end (Fig. 3) . (Fig. 4) elevated in the responders. This indicates that the responders had a relatively high sympathetic acti¬ vity and that when the dopaminergic tone is suppressed, PGE2 is released into circulation.
Indeed, there was a linear correlation between cPGE2 peak and basal NE level in the responders (r = 0.990, < 0.001) (Fig. 7 ). cPGE2 appears to be released at a plasma NE level above 2.4 nmol/1 in control subjects. In contrast, the patients had a lower NE and DA threshold for PGE2 release. This is probably because they have decreased dopaminergic tone even in attack-free periods, which is demonstrated in plasma aldosterone after metoclopramide administration (Fig. 8) (Feuerstein et al. 1982; Vilhardt & Hedqvist 1970 ). Elevation of blood pressure and heart rate, and antidiuretic effect are also reported (Leksell 1976; Hoffman & Schmid 1979 The cPGE2 responses to metoclopramide varied considerably in normal control children. This is in part due to individual variation of the sympathetic activity, but also to age-related changes in dopa¬ minergic tone, which increases progressively with age (study in progress). To match the ages of the patients, control children aged 2-15 years were selected, which might have caused the variation of cPGE2 responsiveness. Even in consideration of this age-related variation, the patients was hypersusceptible to dopaminergic inhibition and showed a low threshold for PGE2 release. An exaggerated response of aldosterone to metoclo¬ pramide also supports their decreased tone of the inhibitory dopaminergic mechanism, since aldo¬ sterone is known to be under the control of dopaminergic inhibition (Carey et al. 1980) . Fur¬ thermore, the therapeutic efficacy of indomethacin rather than clonidine supports the concept that PGE2 release by diminished dopaminergic tone is most crucial as the cause of the disorder than NE release.
In conclusion, we reported 2 patients with a syndrome of periodic CA and PGE2 discharge having the clinical features of recurrent vomit¬ ings, hypertension and psychotic depression. The syndrome appears to be due to a decreased do¬ paminergic inhibitory mechanism in the central
